α-d-xylose 1-phosphate | 27638-61-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: α-d-xylose 1-phosphate
• 英文别名: a-D-xylose 1-phosphate；[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl] dihydrogen phosphate
• CAS: 27638-61-5
• 化学式: C₅H₁₁O₈P
• 分子量: 230.111
• InChiKey: YXJDFQJKERBOBM-KKQCNMDGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  137
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-氨基-7-羟基-3H-嘌呤-6-酮 、 α-d-xylose 1-phosphate 生成 2-amino-9-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]-7-hydroxy-3,6-dihydropurin-9-ium-6-olate
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  adenine xyloside 在 E_. coli purine nucleoside phosphorylase 作用下， 生成 α-d-xylose 1-phosphate 、 腺嘌呤
  参考文献：
  名称：

  Gene Therapy of Cancer: Activation of Nucleoside Prodrugs withE. coliPurine Nucleoside Phosphorylase

  摘要：

  During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery off. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.

  DOI：

  10.1080/15257779908041562

文献信息

• ——
  作者：KITOXARA MIKIRO、 ISII KIENDO、 KAVARADA XADZIMEH、 VATANABEH KIESI

  DOI：——

  日期：——
• Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with<i>E. coli</i>Purine Nucleoside Phosphorylase
  作者：John A. Secrist、William B. Parker、Paula W. Allan、L. Lee Bennett、William R. Waud、Jackie W. Truss、Anita T. Fowler、John A. Montgomery、Steven E. Ealick、Alan H. Wells、G. Yancey Gillespie、V. K. Gadi、Eric J. Sorscher

  DOI：10.1080/15257779908041562

  日期：1999.4

  During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery off. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.